NEW YORK, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that it will report financial results for its fiscal fourth quarter and year-ended September 30, 2017 prior to market open on Friday, December 15, 2017. The Company will also hold a live investor conference call and webcast at 8:30am Eastern Time.
|Conference Call & Webcast|
|Friday, December 15 @ 8:30am Eastern Time|
|Replays – Available through December 22, 2017|
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in an ongoing clinical trial (the MAKO study) for the treatment of the wet form of age-related macular degeneration. Topline data from the MAKO study is expected in early 2018. In addition, Ohr has a sustained-release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com.
Ohr Pharmaceutical, Inc.
LifeSci Advisors, LLC
Source:Ohr Pharmaceutical, Inc.